Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 10/20 | 0.45 |
| ▸ | PPARA | Q07869 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18217 | 1.00 | NPC1 (0.52) | NPC1RAB9APPARGPPARAKDM4E | |
| SCHEMBL26318 | 0.84 | NPC1 (0.53) | NPC1RAB9APPARGPPARAMAOB | |
| SCHEMBL26317 | 0.84 | NPC1 (0.53) | NPC1RAB9APPARGPPARAMAOB | |
| SCHEMBL25344075 | 0.82 | NPC1 (0.50) | NPC1RAB9APPARGPPARAMAOB | |
| SCHEMBL337620 | 0.82 | NPC1 (0.41) | NPC1RAB9APPARGPPARANR1H4 | |
| SCHEMBL1138229 | 0.82 | NPC1 (0.41) | NPC1RAB9APPARGPPARANR1H4 | |
| SCHEMBL166029 | 0.82 | NPC1 (0.41) | NPC1RAB9APPARGPPARANR1H4 | |
| SCHEMBL18243 | 0.82 | NPC1 (0.49) | NPC1RAB9APPARGPPARAMAOB | |
| SCHEMBL3236733 | 0.82 | NPC1 (0.49) | NPC1RAB9APPARGPPARAMAOB | |
| SCHEMBL19566191 | 0.81 | NPC1 (0.48) | NPC1RAB9APPARGPPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646109-A2 | NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS | Invaio Sciences, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| WO-2024168193-A2 | NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS | INVAIO SCIENCES, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| US-20240141370-A1 | AGRICULTURAL COMPOSITIONS AND RELATED METHODS | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2024-05-02 | — | — | US | claimed |
| US-11827897-B2 | Agricultural compositions and related methods | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-11-28 | — | — | US | claimed |
| US-20220064661-A1 | AGRICULTURAL COMPOSITIONS AND RELATED METHODS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-03-03 | — | — | US | claimed |
| EP-2489262-B1 | PESTICIDAL MIXTURES COMPRISING AN ANTHRANILAMIDE INSECTICIDE AND A FUNGICIDE | BASF SE (DE) | 2018-11-14 | — | — | EP | claimed |
| EP-2418944-B1 | METHOD FOR COMBATING HARMFUL FUNGI | BASF SE (DE) | 2017-07-26 | — | — | EP | claimed |
| US-20160186273-A1 | BACILLUS AMYLOLIQUEFACIENS RTI301 COMPOSITIONS AND METHODS OF USE FOR BENEFITING PLANT GROWTH AND TREATING PLANT DISEASE | FMC CORPORATION | 2016-06-30 | — | — | US | claimed |
| US-20160183537-A1 | BACILLUS AMYLOLIQUEFACIENS RTI472 COMPOSITIONS AND METHODS OF USE FOR BENEFITING PLANT GROWTH AND TREATING PLANT DISEASE | FMC CORPORATION | 2016-06-30 | — | — | US | claimed |
| US-9232785-B2 | Method for reducing sunburn damage in plants | BASF SE (DE) | 2016-01-12 | — | — | US | claimed |
| EP-2319320-A1 | Combinations comprising a fungicidal strain and at least one additional fungicide | BASF SE (DE) | 2011-05-11 | — | — | EP | claimed |
| EP-2319319-A1 | Combinations comprising a fungicidal strain and at least one additional fungicide | BASF SE (DE) | 2011-05-11 | — | — | EP | claimed |
| EP-2306832-A2 | SYNERGISTIC FUNGICIDAL MIXTURES | BASF SE (DE) | 2011-04-13 | — | — | EP | claimed |
| WO-2011036111-A2 | METHOD FOR REDUCING PISTILLATE FLOWER ABORTION IN PLANTS | BASF SE (DE) | 2011-03-31 | — | — | WO | claimed |
| WO-2011026796-A1 | SYNERGISTIC FUNGICIDAL MIXTURES COMPRISING LACTYLATES AND METHOD FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2011-03-10 | — | — | WO | claimed |
| EP-2292098-A1 | Combinations comprising a fungicidal strain and at least one additional fungicide | BASF SE (DE) | 2011-03-09 | — | — | EP | claimed |
| EP-2292099-A1 | Combinations comprising a fungicidal strain and at least one additional fungicide | BASF SE (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2011012458-A1 | A METHOD FOR INCREASING THE LEVEL OF FREE AMINO ACIDS IN STORAGE TISSUES OF PERENNIAL PLANTS | BASF SE (DE) | 2011-02-03 | — | — | WO | claimed |
| US-20100273649-A1 | Fungicidal Mixtures III | BASF SE (DE) | 2010-10-28 | — | — | US | claimed |
| EP-1942737-B1 | METHOD OF INDUCING RESISTANCE TO HARMFUL FUNGI | BASF SE (DE) | 2010-03-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186273-A1 | BACILLUS AMYLOLIQUEFACIENS RTI301 COMPOSITIONS AND METHODS OF USE FOR BENEFITING PLANT GROWTH AND TREATING PLANT DISEASE | BTF3, MYB, AGXT | NPC1 4630/4885RAB9A 2307/4885PPARG 1966/4885 |
| US-20100273649-A1 | Fungicidal Mixtures III | CBR3, CBR1, NOX3 | NPC1 993/4885RAB9A 1561/4885PPARG 2657/4885 |
| US-20160183537-A1 | BACILLUS AMYLOLIQUEFACIENS RTI472 COMPOSITIONS AND METHODS OF USE FOR BENEFITING PLANT GROWTH AND TREATING PLANT DISEASE | MYB, BTF3, NRDC | NPC1 4818/4885RAB9A 4301/4885PPARG 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.